Cytogenetics – UroVysionTM Bladder Cancer Assay

The UroVysionTM Bladder Cancer Kit (UroVysionTM Kit) is the first FDA approved diagnostic assay used in the initial diagnosis of bladder cancer in patients presenting hematuria as well as disease monitoring in previously diagnosed patients.
  • Enables earlier detection of recurrence.
  • Detects chromosomal abnormalities associated with the development and recurrence of bladder cancer.
  • Detects tumors that can be overlooked by traditional diagnostic methods.
  • Delivers definitive results (+/-) in suspicious cytoscopy or atypical cytology cases.
  • Shows greater clinical sensitivity when compared to cytoscopy/histology
    Cap Accredited